Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.

Antiviral research - 1 Dec 2017

Hu Longbo, Li Jinqian, Cai Hua, Yao Wenxia, Xiao Jing, Li Yi-Ping, Qiu Xiu, Xia Huimin, Peng Tao

Abstract excerpt

Direct-acting antivirals (DAAs), which target hepatitis C virus (HCV) proteins, have exhibited impressive efficacy in the management of chronic hepatitis C. However, the concerns regarding high costs, drug resistance mutations and subsequent unexpected side effects still call for the development of host-targeting agents (HTAs) that target host factors involved in the viral life cycle and exhibit pan-genotypic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Acetates
Share to Apolipoproteins B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Viral

Share to Sulfonamides

Share to Sulfonic Acids

Share to Virion

Share to Virus Assembly

Source

Identifiers

PMID: 29074218
DOI: 10.1016/j.antiviral.2017.10.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.PMID 29074218Read ↗

Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies.Semantic proximity Read ↗

Hepatitis C Virus Life Cycle and Lipid MetabolismSemantic proximity Read ↗

Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins.Semantic proximity Read ↗

Reliance of Host Cholesterol Metabolic Pathways for the Life Cycle of Hepatitis C VirusSemantic proximity Read ↗

Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.Semantic proximity Read ↗

Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core.Semantic proximity Read ↗

Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C virusesSemantic proximity Read ↗

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeSemantic proximity Read ↗

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activitySemantic proximity Read ↗

Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C VirusSemantic proximity Read ↗

Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replicationSemantic proximity Read ↗

Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.